Ciro Rincon-Prieto, MD
Pulmonary Disease · Columbus, MSNPI 1396097788
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 417 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AstraZeneca at 25.0% of the total. 2025 is the largest year on record at $2,025, 2.6 times the $768 reported in 2019.
Across 417 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Sanofi$553
- Boehringer Ingelheim$549
- Mallinckrodt Hospital Products Inc.$389
- Philips North America LLC$313
- plus $2K from 20 others
What the payments were for
- Food & beverage$6,972100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 93 | $1,744 |
| GSK | 106 | $1,367 |
| Sanofi | 34 | $553 |
| Boehringer Ingelheim | 34 | $549 |
| Mallinckrodt Hospital Products Inc. | 24 | $389 |
| Philips North America LLC | 17 | $313 |
| Grifols USA, LLC | 12 | $249 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $241 |
| Mylan Specialty L.p. | 11 | $225 |
| Verona Pharma, Inc. | 13 | $192 |
| Ceribell, Inc. | 1 | $128 |
| Regeneron Healthcare Solutions, Inc. | 6 | $113 |
| United Therapeutics Corporation | 6 | $102 |
| Insmed, Inc. | 6 | $101 |
| Bayer | 5 | $87 |
| Amgen | 5 | $83 |
| Merck | 5 | $77 |
| Novartis | 5 | $72 |
| Abiomed | 3 | $67 |
| Vifor Pharma, Inc. | 3 | $66 |
| Viatris Specialty LLC | 3 | $58 |
| Electromed, Inc. | 3 | $50 |
| AbbVie | 3 | $44 |
| Boston Scientific | 1 | $39 |
| Pfizer | 2 | $36 |
| Shire North American Group Inc | 2 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,972 in reported general payments places this provider in the 55th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 30 | $361,067 |
| Dupixent PenDupilumab | 61 | $237,156 |
| ZemairaAlpha-1-Proteinase Inhibitor | 14 | $145,971 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $120,677 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 150 | $110,390 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 150 | $100,334 |
| Fasenra PenBenralizumab | 18 | $97,772 |
| Breo ElliptaFluticasone/Vilanterol | 133 | $63,558 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 84 | $43,612 |
| Spiriva RespimatTiotropium Bromide | 48 | $29,557 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 47 | $22,208 |
| SymbicortBudesonide/Formoterol Fumarate | 59 | $16,679 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 439 | $12,020 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 22 | $9,228 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 46 | $9,222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $549 | $412,832125 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,367 | $215,488390 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,744 | $136,297231 claims |
| Grifols USA, LLCProlastin C | $249 | $120,67713 claims |
| MerckDulera | $77 | $8,12422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Columbus
- Ana Bonetti LugoColumbus$14K
- Christopher RailwahColumbus$11K
- Yash SardaColumbus$4K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
- Bobby TullosGulfport$276K
- Michal SenitkoJackson$185K
- Cameron HuxfordStarkville$155K
- L AldredHattiesburg$76K
- Andrew WilhelmJackson$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.